声动力疗法
代谢组
肝细胞癌
癌症研究
代谢组学
转录组
糖酵解
药理学
谷胱甘肽
细胞凋亡
联合疗法
化学
代谢物
代谢途径
医学
新陈代谢
细胞培养
细胞毒性
厌氧糖酵解
作者
Haoyan Tan,Huimin Tian,Yichi Chen,Bolin Wu,Wen Cheng,Haitao Shang
出处
期刊:Drug Delivery
[Taylor & Francis]
日期:2025-12-03
卷期号:32 (1): 2593600-2593600
被引量:1
标识
DOI:10.1080/10717544.2025.2593600
摘要
Sonodynamic therapy (SDT) has emerged as a promising approach for treating hepatocellular carcinoma (HCC) by combining sonosensitizers with low-intensity ultrasound. However, SDT alone could not achieve satisfactory results. Here, we developed novel nanobubbles loaded with hematoporphyrin monomethyl ether (HMME@NBs) and evaluated its therapeutic potential in combination with the glycolytic inhibitor lonidamine (LND) against HCC. The HMME@NBs was successfully prepared with particle size of 410.58 ± 20.07 nm and zeta potential at -8.38 ± 1.12mV. The encapsulation efficiency and loading efficiency of HMME was 80.6% and 7.12%, respectively. Both in vitro and in vivo studies demonstrated that while SDT and LND monotherapies inhibited the growth of HepG2 cells and xenograft tumors in nude mice, the combination therapy exhibited the most significant inhibitory effect. Multi-omics analysis of tumor tissues revealed substantial alterations in metabolites and gene expression, with key pathways such as glutathione metabolism implicated in the treatment response. Our findings highlight the enhanced antitumor efficacy of HMME@NBs-mediated SDT combined with LND, supported by mechanistic insights from transcriptomic and metabolomic profiling. This synergistic strategy holds great potential for HCC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI